Physical stability and recrystallization kinetics of amorphous ibipinabant drug product by Fourier transform Raman spectroscopy

Journal of Pharmaceutical Sciences

Volumn 100, Issue 11, 2011, Pages 4687-4699

  Sinclair, Wayne ^a   Leane, Michael ^a   Clarke, Graham ^a   Dennis, Andrew ^a   Tobyn, Mike ^a   Timmins, Peter ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Amorphous; Avrami kinetics; Chemometrics; FT Raman spectroscopy; Ibipinabant; Physical stability; Raman microscopy; Recrystallization; Solid state kinetics

Indexed keywords

IBIPINABANT; POVIDONE;

ARTICLE; CONCENTRATION (PARAMETERS); CRYSTALLIZATION; DISPERSION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; FOURIER TRANSFORMATION; HUMIDITY; MATHEMATICAL MODEL; MOISTURE; RAMAN SPECTROMETRY; TABLET; TEMPERATURE;

EID: 80053267913     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22658     Document Type: Article

References (26)

1. Serajuddin ATM. 1999. Solid dispersion of poor water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
2. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
3. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Delivery Rev 48:27-42.
4. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
5. Yoshioka S, Stella VJ. 2000. Stability of drugs and dosage forms. New York: Kluwer Academic/Plenum Publishers, pp 139-150.
6. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97:1329-1349.
7. Ahlneck C, Zografi G. 1990. The molecular basis for moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm 62:87-95.
8. Carstensen JT. 1995. Drug stability: Principles and practices. 2nd ed. New York: Marcel Dekker.
9. Feth PF, Volz J, Hess U, Sturm E, Hummel RF. 2007. Physicochemical, crystallographic, thermal, and spectroscopic behaviour of crystalline and x-ray amorphous ciclesonide. J Pharm Sci 97(9):3765-3780.
10. Shah B, Kakumanu VK, Bansal AK. 2006. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 95(8):1641-1665.
11. Miyazaki T, Yoshioka S, Aso Y, Kawanishi T. 2007. Crystallization rate of amorphous nifedipine analogues unrelated to the glass transition temperature. Int J Pharm 336:191-195.
12. Ito A, Watanabe T, Yada S, Hamaura T, Nakagami H, Higashi K, Moribe K, Yamamoto K. 2010. Prediction of recrystallization behaviour of troglitazone/polyvinylpyrrolidone solid dispersion by solid-state NMR. Int J Pharm 383: 18-23.
13. Taylor LS, Langkilde FW. 2000. Evaluation of solid-state forms present in tablets by Raman spectroscopy. J Pharm Sci 89(10):1342-1353.
14. Taylor LS, Zografi G. 1998. The quantitative analysis of crystallinity using FT-Raman spectroscopy. Pharm Res 15(5):755-761.
15. Okumara T, Otsuka M. 2005. Evaluation of microcrystallinity of a drug substance, indomethacin, in a pharmaceutical model tablet by chemometric FT-Raman spectroscopy. Pharm Res 22(8):1350-1357.
16. Otsuka M, Kato F, Matsuda Y. 2002. Physiochemical stability of cimetidine amorphous forms estimated by isothermal microcalorimetry. AAP PharmSciTech 3(4):1-13.
17. Feth MP, Volz J, Hess U, Sturm E, Hummel RP. 2008. Physicochemical, crystallographic, thermal, and spectroscopic behaviour of crystalline and X-ray amorphous ciclesonide. J Pharm Sci 97(9):3765-3780.
18. Yang J, Grey K, Doney J. 2010. An improved kinetics approach to describe the physical stability of amorphous solid dispersions. Int J Pharm 384:24-31.
19. Fakes MG, Blisse JV, Qian F, Desikan S, Gandhi RB, Lai C, Hsieh A, Franchini MK, Toale H, Brown J. 2009. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm 370:167-174.
20. Tobyn M, Brown J, Dennis A, Fakes M, Gao Q, Gamble J, Khimyak Y, McGeorge G, Patel C, Sinclair W, Timmins P, Yin S. 2009. Amorphous drug-PVP dispersions: Application of theoretical, thermal and spectroscopic analytical techniques to study of a molecule with intermolecular bonds in both crystalline and pure amorphous state. J Pharm Sci 98(9):3456-3468.
21. ICH Guideline Q1A (R2), Stability testing of new drug substances and products. CPMP/ICH/2736/99 and the effective date August 2003.
22. Avrami M. 1939. Kinetics of phase change. I General theory. J Chem Phys 7:1103-1112.
23. Avrami, M. 1940. Kinetics of phase change. II Transformation-time relations for random distribution of nuclei. J Chem Phys 8:212-224.
24. Avrami M. 1941. Kinetics of phase change. III Granulation, phase change, and microstructure. J Chem Phys 9:177-184.
25. Johnson WA, Mehl RF. 1939. Reaction kinetics in processes of nucleation and growth. Trans Am Inst Min Eng 123:416-441.
26. Maffezzoli A, Kenny JM, Torre L. 1995. On the physical dimensions of the Avrami constant. Thermochim Acta 269/270:185-190.